Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
CALCIMEDICA INC Market Cap
The CALCIMEDICA INC (CALC) share price is expected to increase by 518.18% over the next year. This is based on calculating the average 12-month share price estimate provided by 3 stock analysts who have covered CALC. Price targets range from $15 at the low end to $20 at the high end. The current analyst consensus for CALC is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
CALCIMEDICA INC has a total of 3 Wall St Analyst ratings. There are 3 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that CALCIMEDICA INC will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CALC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $16 | Reiterates | Nov 14, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $16 | Maintains | Nov 4, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $20 | Reiterates | Aug 13, 2024 |
| Leland Gershell Oppenheimer | Outperform | $20 | Maintains | Jul 10, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $20 | Reiterates | Jul 9, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $20 | Reiterates | Jun 27, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $20 | Reiterates | May 14, 2024 |
| Leland Gershell Oppenheimer | Outperform | $14 | Maintains | Apr 1, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $20 | Reiterates | Apr 1, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $20 | Reiterates | Mar 13, 2024 |
| Catherine Novack JonesTrading | Buy | $22 | Initiates | Feb 16, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $20 | Reiterates | Feb 13, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $20 | Initiates | Jan 29, 2024 |
| Leland Gershell Oppenheimer | Outperform | $14 | Reiterates | Nov 13, 2023 |
EF Hutton | Buy | Reiterates | Jul 7, 2023 | |
EF Hutton | Buy | Initiates | Jun 20, 2023 | |
Oppenheimer | Outperform | Reiterates | May 16, 2023 | |
| Leland Gershell Oppenheimer | Outperform | $14 | Initiates | Mar 24, 2023 |
When did it IPO
2023
Staff Count
13
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. A. Rachel Leheny Ph.D.
Market Cap
$44.9M
In 2023, CALC generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CALC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - CalciMedica Inc. will present findings from the Phase 2b CARPO trial of Auxora™ for Acute Pancreatitis at two upcoming medical conferences in December 2024.
Why It Matters - The presentation of the CARPO trial results could indicate progress in CalciMedica's drug development, potentially influencing stock performance and investor sentiment in the biopharmaceutical sector.
Thu, 21 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - CalciMedica Inc. (Nasdaq: CALC) announced the appointment of Rachel Leheny, Ph.D., as part of its focus on CRAC channel inhibition therapies for inflammatory and immunologic diseases.
Why It Matters - CalciMedica's focus on CRAC channel inhibitors in treating inflammatory and immunologic diseases highlights potential growth opportunities in the biotech sector, impacting stock performance and investor interest.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - CalciMedica reported positive data from its CARPO Phase 2b trial for Auxora™ in acute pancreatitis, with plans to start Phase 3 in 2025. Current cash funds operations into mid-2026.
Why It Matters - Positive trial data for Auxora™ boosts confidence in CalciMedica's pipeline, while funding through 2026 ensures operational stability, potentially increasing investor interest and stock value.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - CalciMedica, Inc. appointed Stephen Bardin as CFO, replacing Interim CFO Daniel Geffken, effective after the third quarter financial statement filing.
Why It Matters - Leadership changes can impact a company's strategic direction and financial management. Investors may react to new CFOs based on their track records and potential influence on future performance.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - CalciMedica Inc. (Nasdaq: CALC) has initiated an underwritten public offering of its common stock, aimed at funding its CRAC channel inhibition therapies for inflammatory and immunologic diseases.
Why It Matters - CalciMedica's public offering can dilute existing shares, impact stock price, and signal funding needs for ongoing research, affecting investor sentiment and potential returns.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - CalciMedica, Inc. (Nasdaq: CALC) has announced a public offering of 2,720,000 shares at $3.75 each to fund its development of CRAC channel inhibition therapies for inflammatory conditions.
Why It Matters - CalciMedica's public offering at $3.75 per share indicates a potential dilution of existing shares, impacting stock value and signaling capital needs for ongoing development.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
